Prognostically relevant gene signatures of high-grade serous ovarian carcinoma

Roel G W Verhaak, Pablo Tamayo, Ji Yeon Yang, Diana Hubbard, Hailei Zhang, Chad J. Creighton, Sian Fereday, Michael Lawrence, Scott L. Carter, Craig H. Mermel, Aleksandar D. Kostic, Dariush Etemadmoghadam, Gordon Saksena, Kristian Cibulskis, Sekhar Duraisamy, Keren Levanon, Carrie Sougnez, Aviad Tsherniak, Sebastian Gomez, Robert OnofrioStacey Gabriel, Lynda Chin, Nianxiang Zhang, Paul Spellman, Yiqun Zhang, Rehan Akbani, Katherine A. Hoadley, Ari Kahn, Martin Köbel, David Huntsman, Robert A. Soslow, Anna Defazio, Michael J. Birrer, Joe Gray, John N. Weinstein, David D. Bowtell, Ronny Drapkin, Jill P. Mesirov, Gad Getz, Douglas A. Levine, Matthew Meyerson

Research output: Contribution to journalArticle

269 Citations (Scopus)

Abstract

Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named "Classification of Ovarian Cancer" (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.

Original languageEnglish (US)
Pages (from-to)517-525
Number of pages9
JournalJournal of Clinical Investigation
Volume123
Issue number1
DOIs
StatePublished - Jan 2 2013

Fingerprint

Ovarian Neoplasms
Carcinoma
Genes
Platinum
Survival
Atlases
Transcriptome
Neoplasms
Genome
Recurrence
Mutation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Verhaak, R. G. W., Tamayo, P., Yang, J. Y., Hubbard, D., Zhang, H., Creighton, C. J., ... Meyerson, M. (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 123(1), 517-525. https://doi.org/10.1172/JCI65833

Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. / Verhaak, Roel G W; Tamayo, Pablo; Yang, Ji Yeon; Hubbard, Diana; Zhang, Hailei; Creighton, Chad J.; Fereday, Sian; Lawrence, Michael; Carter, Scott L.; Mermel, Craig H.; Kostic, Aleksandar D.; Etemadmoghadam, Dariush; Saksena, Gordon; Cibulskis, Kristian; Duraisamy, Sekhar; Levanon, Keren; Sougnez, Carrie; Tsherniak, Aviad; Gomez, Sebastian; Onofrio, Robert; Gabriel, Stacey; Chin, Lynda; Zhang, Nianxiang; Spellman, Paul; Zhang, Yiqun; Akbani, Rehan; Hoadley, Katherine A.; Kahn, Ari; Köbel, Martin; Huntsman, David; Soslow, Robert A.; Defazio, Anna; Birrer, Michael J.; Gray, Joe; Weinstein, John N.; Bowtell, David D.; Drapkin, Ronny; Mesirov, Jill P.; Getz, Gad; Levine, Douglas A.; Meyerson, Matthew.

In: Journal of Clinical Investigation, Vol. 123, No. 1, 02.01.2013, p. 517-525.

Research output: Contribution to journalArticle

Verhaak, RGW, Tamayo, P, Yang, JY, Hubbard, D, Zhang, H, Creighton, CJ, Fereday, S, Lawrence, M, Carter, SL, Mermel, CH, Kostic, AD, Etemadmoghadam, D, Saksena, G, Cibulskis, K, Duraisamy, S, Levanon, K, Sougnez, C, Tsherniak, A, Gomez, S, Onofrio, R, Gabriel, S, Chin, L, Zhang, N, Spellman, P, Zhang, Y, Akbani, R, Hoadley, KA, Kahn, A, Köbel, M, Huntsman, D, Soslow, RA, Defazio, A, Birrer, MJ, Gray, J, Weinstein, JN, Bowtell, DD, Drapkin, R, Mesirov, JP, Getz, G, Levine, DA & Meyerson, M 2013, 'Prognostically relevant gene signatures of high-grade serous ovarian carcinoma', Journal of Clinical Investigation, vol. 123, no. 1, pp. 517-525. https://doi.org/10.1172/JCI65833
Verhaak RGW, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation. 2013 Jan 2;123(1):517-525. https://doi.org/10.1172/JCI65833
Verhaak, Roel G W ; Tamayo, Pablo ; Yang, Ji Yeon ; Hubbard, Diana ; Zhang, Hailei ; Creighton, Chad J. ; Fereday, Sian ; Lawrence, Michael ; Carter, Scott L. ; Mermel, Craig H. ; Kostic, Aleksandar D. ; Etemadmoghadam, Dariush ; Saksena, Gordon ; Cibulskis, Kristian ; Duraisamy, Sekhar ; Levanon, Keren ; Sougnez, Carrie ; Tsherniak, Aviad ; Gomez, Sebastian ; Onofrio, Robert ; Gabriel, Stacey ; Chin, Lynda ; Zhang, Nianxiang ; Spellman, Paul ; Zhang, Yiqun ; Akbani, Rehan ; Hoadley, Katherine A. ; Kahn, Ari ; Köbel, Martin ; Huntsman, David ; Soslow, Robert A. ; Defazio, Anna ; Birrer, Michael J. ; Gray, Joe ; Weinstein, John N. ; Bowtell, David D. ; Drapkin, Ronny ; Mesirov, Jill P. ; Getz, Gad ; Levine, Douglas A. ; Meyerson, Matthew. / Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. In: Journal of Clinical Investigation. 2013 ; Vol. 123, No. 1. pp. 517-525.
@article{b7d2fedc8d6342df9cabd7cab943ccef,
title = "Prognostically relevant gene signatures of high-grade serous ovarian carcinoma",
abstract = "Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named {"}Classification of Ovarian Cancer{"} (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23{\%} of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63{\%}, versus a median survival of 46 months and platinum resistance rate of 23{\%} in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.",
author = "Verhaak, {Roel G W} and Pablo Tamayo and Yang, {Ji Yeon} and Diana Hubbard and Hailei Zhang and Creighton, {Chad J.} and Sian Fereday and Michael Lawrence and Carter, {Scott L.} and Mermel, {Craig H.} and Kostic, {Aleksandar D.} and Dariush Etemadmoghadam and Gordon Saksena and Kristian Cibulskis and Sekhar Duraisamy and Keren Levanon and Carrie Sougnez and Aviad Tsherniak and Sebastian Gomez and Robert Onofrio and Stacey Gabriel and Lynda Chin and Nianxiang Zhang and Paul Spellman and Yiqun Zhang and Rehan Akbani and Hoadley, {Katherine A.} and Ari Kahn and Martin K{\"o}bel and David Huntsman and Soslow, {Robert A.} and Anna Defazio and Birrer, {Michael J.} and Joe Gray and Weinstein, {John N.} and Bowtell, {David D.} and Ronny Drapkin and Mesirov, {Jill P.} and Gad Getz and Levine, {Douglas A.} and Matthew Meyerson",
year = "2013",
month = "1",
day = "2",
doi = "10.1172/JCI65833",
language = "English (US)",
volume = "123",
pages = "517--525",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Prognostically relevant gene signatures of high-grade serous ovarian carcinoma

AU - Verhaak, Roel G W

AU - Tamayo, Pablo

AU - Yang, Ji Yeon

AU - Hubbard, Diana

AU - Zhang, Hailei

AU - Creighton, Chad J.

AU - Fereday, Sian

AU - Lawrence, Michael

AU - Carter, Scott L.

AU - Mermel, Craig H.

AU - Kostic, Aleksandar D.

AU - Etemadmoghadam, Dariush

AU - Saksena, Gordon

AU - Cibulskis, Kristian

AU - Duraisamy, Sekhar

AU - Levanon, Keren

AU - Sougnez, Carrie

AU - Tsherniak, Aviad

AU - Gomez, Sebastian

AU - Onofrio, Robert

AU - Gabriel, Stacey

AU - Chin, Lynda

AU - Zhang, Nianxiang

AU - Spellman, Paul

AU - Zhang, Yiqun

AU - Akbani, Rehan

AU - Hoadley, Katherine A.

AU - Kahn, Ari

AU - Köbel, Martin

AU - Huntsman, David

AU - Soslow, Robert A.

AU - Defazio, Anna

AU - Birrer, Michael J.

AU - Gray, Joe

AU - Weinstein, John N.

AU - Bowtell, David D.

AU - Drapkin, Ronny

AU - Mesirov, Jill P.

AU - Getz, Gad

AU - Levine, Douglas A.

AU - Meyerson, Matthew

PY - 2013/1/2

Y1 - 2013/1/2

N2 - Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named "Classification of Ovarian Cancer" (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.

AB - Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named "Classification of Ovarian Cancer" (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=84873862912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873862912&partnerID=8YFLogxK

U2 - 10.1172/JCI65833

DO - 10.1172/JCI65833

M3 - Article

C2 - 23257362

AN - SCOPUS:84873862912

VL - 123

SP - 517

EP - 525

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -